![]() Our score, based on the PEGASUS-TIMI 54 criteria, may identify AMI patients at high risk of recurrent ischemic events, who might benefit from thorough preventive strategies.Īcute myocardial infarction PEGASUS-TIMI 54 Prognosis Risk score.Ĭopyright © 2018 Elsevier B.V. PEGASUS TIMI 54 TRIALThe prognostic performance of the score cut-off persisted beyond the first year after AMI in the validation cohort, maintaining a similar risk for death and non-fatal AMI (HR 3) at every following year. The analysis of the PEGASUS-TIMI 54 trial looked at the 21,162 patients with a history of myocardial infarction (MI) who were randomly assigned to a twice-daily regimen of ticagrelor at 90 mg, ticagrelor at 60 mg or placebo. One-year major bleeding rate was low (<0.2% overall) and similar between risk groups. At multivariate analysis, the HR for the primary endpoint associated with a score ≥ 6 was 4.45 (P < 0.0001) in the derivation cohort and 2.86 (P < 0.0001) in the validation cohort. LONDON (dpa-AFX) - AstraZeneca (AZN, AZN. The primary endpoint incidence in patients with a score above and below the cut-off was 12% and 3% (P < 0.001) in the derivation cohort and 16% and 6% in the validation cohort (P < 0.001). In the derivation cohort, the area under the curve of the score for the primary endpoint (1-year death and non-fatal AMI) was 0.70 (95% CI 0.65-0.76 P < 0.0001) and a cut-off of 6 was identified. We externally validated our score in 913 AMI patients with a longer follow-up. We calculated a cut-off for the developed score and investigated its 1-year prognostic power in the derivation cohort (n = 1257). BRILINTA 60mg and 90mg demonstrate statistically significant reduction in major cardiovascular thrombotic events in patients with a history of heart attack. PEGASUS TIMI 54 FULLWe retrospectively analyzed two prospectively collected AMI cohorts. london (dpa-afx) - astrazeneca (azn, azn.l) announced full results from the pegasus-timi 54 study, a large-scale outcomes trial that investigated brilinta (ticagrelor) tablets plus low dose. CHICAGO Two subanalyses of the PEGASUS-TIMI 54 study of stable patients with prior MI showed that ticagrelor reduced major adverse CV events in patients with a history of diabetes or. We aimed to elaborate a risk score, based on the PEGASUS-TIMI 54 criteria, to predict mortality and non-fatal AMI in AMI patients. Acute myocardial infarction (AMI) patients are at increased risk of death and recurrent ischemic events. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |